Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 1/20 | 0.44 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
| ▸ | LOXL2 | Q9Y4K0 | 4/20 | 0.41 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.38 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
| ▸ | F2 | P00734 | 1/20 | 0.37 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.37 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.37 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.37 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.37 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.37 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.37 |
| ▸ | VDR | P11473 | 1/20 | 0.37 |
| ▸ | PPARD | Q03181 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5131714 | 0.90 | PTGES2 (0.47) | PIK3CAPTGES2CYP11B1CYP11B2LOXL2 | |
| SCHEMBL4430740 | 0.88 | LOXL2 (0.48) | LOXL2PTGDR2PTGS1AKR1C3AKR1C2 | |
| SCHEMBL4435043 | 0.88 | PIK3CA (0.46) | PIK3CAPTGES2CYP11B1CYP11B2LOXL2 | |
| SCHEMBL4438508 | 0.86 | PTGER2 (0.46) | CYP11B1CYP11B2LOXL2PTGDR2PTGS1 | |
| SCHEMBL4428902 | 0.86 | MMP2 (0.50) | CYP11B1CYP11B2LOXL2PTGDR2PTGS1 | |
| SCHEMBL4434979 | 0.84 | DAGLA (0.43) | LOXL2PTGDR2PTGS1AKR1C3AKR1C2 | |
| SCHEMBL4439777 | 0.83 | FFAR1 (0.44) | CYP11B1CYP11B2PTGDR2PTGS1AKR1C3 | |
| SCHEMBL4433212 | 0.83 | RXRA (0.43) | CYP11B1CYP11B2LOXL2PTGDR2PTGS1 | |
| SCHEMBL4430445 | 0.83 | ACLY (0.43) | CYP11B1CYP11B2LOXL2PTGDR2 | |
| SCHEMBL5131711 | 0.81 | PIK3CA (0.44) | PIK3CAPTGES2CYP11B1CYP11B2NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2121591-A2 | PPAR ACTIVE COMPOUNDS | PLEXXIKON, INC. (US) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008109697-A2 | PPAR ACTIVE COMPOUNDS | PLEXXIKON, INC. (US) | 2008-09-12 | — | — | WO | disclosed |
| US-20080221127-A1 | peroxisome proliferator-activated receptor agonists; congestive heart failure, atherosclerosis, arteriosclerosis, obesity, hyperlipidemia, hypoalphalipoproteinemia, Syndrome X, diabetes, insulin resistance | PLEXXIKON INC | 2008-09-11 | — | — | US | disclosed |
| US-20080221127-A1 | peroxisome proliferator-activated receptor agonists; congestive heart failure, atherosclerosis, arteriosclerosis, obesity, hyperlipidemia, hypoalphalipoproteinemia, Syndrome X, diabetes, insulin resistance | PLEXXIKON INC | 2008-09-11 | — | — | US | disclosed |
| US-20080221127-A1 | peroxisome proliferator-activated receptor agonists; congestive heart failure, atherosclerosis, arteriosclerosis, obesity, hyperlipidemia, hypoalphalipoproteinemia, Syndrome X, diabetes, insulin resistance | PLEXXIKON INC | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221127-A1 | peroxisome proliferator-activated receptor agonists; congestive heart failure, atherosclerosis, arteriosclerosis, obesity, hyperlipidemia, hypoalphalipoproteinemia, Syndrome X, diabetes, insulin resistance | PPARA, PPARG, PPARD | PIK3CA 958/4885PTGES2 733/4885CYP11B1 572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.